Updated:
Immuron Ltd
Immuron Ltd is a publicly traded Australian biopharmaceutical firm (ASX: IMC) that develops oral immunotherapies targeting enteric diseases such as...
Overview
Immuron Ltd is a publicly traded Australian biopharmaceutical firm (ASX: IMC) that develops oral immunotherapies targeting enteric diseases such as traveler's diarrhea and Clostridium difficile infection. The company's lead product, Travelan, is an over-the-counter oral antibody derived from bovine colostrum.
General information
Frequently asked questions
What does Immuron Ltd do?
Immuron develops oral immunotherapies for gastrointestinal infections, including Travelan for traveler's diarrhea and a therapeutic for C. difficile infection. Its products are based on hyperimmune bovine colostrum technology.
Who are Immuron Ltd's key executives?
As of public filings, key personnel include CEO and Managing Director Steven Lydeamore. No named investment principals or family-office-related individuals are disclosed.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: